The global market for Oligonucleotide Therapy was estimated to be worth US$ 3678.1 million in 2023 and is forecast to a readjusted size of US$ 4746.7 million by 2030 with a CAGR of 3.6% during the forecast period 2024-2030

Oligonucleotide Therapy - Market

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oligonucleotide Therapy by region & country, by Type, and by Application.

The Oligonucleotide Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapy.

Market Segmentation

Scope of Oligonucleotide Therapy - Market Report

Report Metric	Details
Report Name	Oligonucleotide Therapy - Market
Forecasted market size in 2030	US$ 4746.7 million
CAGR	3.6%
Forecasted years	2024 - 2030
Segment by Type:	Antisense Oligonucleotide Aptamer Others
Segment by Application	Infectious Diseases Oncology Neurodegenerative Disorders Cardiovascular Diseases Kidney Diseases Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Alnylam Pharmaceuticals Inc., Biogen, Dynavax Technologies Corp., Merck and Co., Miragen Therapeuutics Inc., Sarepta Therapeutics Inc., GlaxoSmithKline, Pfizer, Gilead Sciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oligonucleotide Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Oligonucleotide Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Oligonucleotide Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Oligonucleotide Therapy - Market size in 2030?

Ans: The Oligonucleotide Therapy - Market size in 2030 will be US$ 4746.7 million.

Who are the main players in the Oligonucleotide Therapy - Market report?

Ans: The main players in the Oligonucleotide Therapy - Market are Alnylam Pharmaceuticals Inc., Biogen, Dynavax Technologies Corp., Merck and Co., Miragen Therapeuutics Inc., Sarepta Therapeutics Inc., GlaxoSmithKline, Pfizer, Gilead Sciences

What are the Application segmentation covered in the Oligonucleotide Therapy - Market report?

Ans: The Applications covered in the Oligonucleotide Therapy - Market report are Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others

What are the Type segmentation covered in the Oligonucleotide Therapy - Market report?

Ans: The Types covered in the Oligonucleotide Therapy - Market report are Antisense Oligonucleotide, Aptamer, Others

1 Market Overview

1.1 Oligonucleotide Therapy Product Introduction

1.2 Global Oligonucleotide Therapy Market Size Forecast

1.3 Oligonucleotide Therapy Market Trends & Drivers

1.3.1 Oligonucleotide Therapy Industry Trends

1.3.2 Oligonucleotide Therapy Market Drivers & Opportunity

1.3.3 Oligonucleotide Therapy Market Challenges

1.3.4 Oligonucleotide Therapy Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Oligonucleotide Therapy Players Revenue Ranking (2023)

2.2 Global Oligonucleotide Therapy Revenue by Company (2019-2024)

2.3 Key Companies Oligonucleotide Therapy Manufacturing Base Distribution and Headquarters

2.4 Key Companies Oligonucleotide Therapy Product Offered

2.5 Key Companies Time to Begin Mass Production of Oligonucleotide Therapy

2.6 Oligonucleotide Therapy Market Competitive Analysis

2.6.1 Oligonucleotide Therapy Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Oligonucleotide Therapy Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapy as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Antisense Oligonucleotide

3.1.2 Aptamer

3.1.3 Others

3.2 Global Oligonucleotide Therapy Sales Value by Type

3.2.1 Global Oligonucleotide Therapy Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Oligonucleotide Therapy Sales Value, by Type (2019-2030)

3.2.3 Global Oligonucleotide Therapy Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Infectious Diseases

4.1.2 Oncology

4.1.3 Neurodegenerative Disorders

4.1.4 Cardiovascular Diseases

4.1.5 Kidney Diseases

4.1.6 Others

4.2 Global Oligonucleotide Therapy Sales Value by Application

4.2.1 Global Oligonucleotide Therapy Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Oligonucleotide Therapy Sales Value, by Application (2019-2030)

4.2.3 Global Oligonucleotide Therapy Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Oligonucleotide Therapy Sales Value by Region

5.1.1 Global Oligonucleotide Therapy Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Oligonucleotide Therapy Sales Value by Region (2019-2024)

5.1.3 Global Oligonucleotide Therapy Sales Value by Region (2025-2030)

5.1.4 Global Oligonucleotide Therapy Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Oligonucleotide Therapy Sales Value, 2019-2030

5.2.2 North America Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Oligonucleotide Therapy Sales Value, 2019-2030

5.3.2 Europe Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Oligonucleotide Therapy Sales Value, 2019-2030

5.4.2 Asia Pacific Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Oligonucleotide Therapy Sales Value, 2019-2030

5.5.2 South America Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Oligonucleotide Therapy Sales Value, 2019-2030

5.6.2 Middle East & Africa Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Oligonucleotide Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Oligonucleotide Therapy Sales Value

6.3 United States

6.3.1 United States Oligonucleotide Therapy Sales Value, 2019-2030

6.3.2 United States Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Oligonucleotide Therapy Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Oligonucleotide Therapy Sales Value, 2019-2030

6.4.2 Europe Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Oligonucleotide Therapy Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Oligonucleotide Therapy Sales Value, 2019-2030

6.5.2 China Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

6.5.3 China Oligonucleotide Therapy Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Oligonucleotide Therapy Sales Value, 2019-2030

6.6.2 Japan Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Oligonucleotide Therapy Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Oligonucleotide Therapy Sales Value, 2019-2030

6.7.2 South Korea Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Oligonucleotide Therapy Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Oligonucleotide Therapy Sales Value, 2019-2030

6.8.2 Southeast Asia Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Oligonucleotide Therapy Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Oligonucleotide Therapy Sales Value, 2019-2030

6.9.2 India Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

6.9.3 India Oligonucleotide Therapy Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Alnylam Pharmaceuticals Inc.

7.1.1 Alnylam Pharmaceuticals Inc. Profile

7.1.2 Alnylam Pharmaceuticals Inc. Main Business

7.1.3 Alnylam Pharmaceuticals Inc. Oligonucleotide Therapy Products, Services and Solutions

7.1.4 Alnylam Pharmaceuticals Inc. Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.1.5 Alnylam Pharmaceuticals Inc. Recent Developments

7.2 Biogen

7.2.1 Biogen Profile

7.2.2 Biogen Main Business

7.2.3 Biogen Oligonucleotide Therapy Products, Services and Solutions

7.2.4 Biogen Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.2.5 Biogen Recent Developments

7.3 Dynavax Technologies Corp.

7.3.1 Dynavax Technologies Corp. Profile

7.3.2 Dynavax Technologies Corp. Main Business

7.3.3 Dynavax Technologies Corp. Oligonucleotide Therapy Products, Services and Solutions

7.3.4 Dynavax Technologies Corp. Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.3.5 Merck and Co. Recent Developments

7.4 Merck and Co.

7.4.1 Merck and Co. Profile

7.4.2 Merck and Co. Main Business

7.4.3 Merck and Co. Oligonucleotide Therapy Products, Services and Solutions

7.4.4 Merck and Co. Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.4.5 Merck and Co. Recent Developments

7.5 Miragen Therapeuutics Inc.

7.5.1 Miragen Therapeuutics Inc. Profile

7.5.2 Miragen Therapeuutics Inc. Main Business

7.5.3 Miragen Therapeuutics Inc. Oligonucleotide Therapy Products, Services and Solutions

7.5.4 Miragen Therapeuutics Inc. Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.5.5 Miragen Therapeuutics Inc. Recent Developments

7.6 Sarepta Therapeutics Inc.

7.6.1 Sarepta Therapeutics Inc. Profile

7.6.2 Sarepta Therapeutics Inc. Main Business

7.6.3 Sarepta Therapeutics Inc. Oligonucleotide Therapy Products, Services and Solutions

7.6.4 Sarepta Therapeutics Inc. Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.6.5 Sarepta Therapeutics Inc. Recent Developments

7.7 GlaxoSmithKline

7.7.1 GlaxoSmithKline Profile

7.7.2 GlaxoSmithKline Main Business

7.7.3 GlaxoSmithKline Oligonucleotide Therapy Products, Services and Solutions

7.7.4 GlaxoSmithKline Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.7.5 GlaxoSmithKline Recent Developments

7.8 Pfizer

7.8.1 Pfizer Profile

7.8.2 Pfizer Main Business

7.8.3 Pfizer Oligonucleotide Therapy Products, Services and Solutions

7.8.4 Pfizer Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.8.5 Pfizer Recent Developments

7.9 Gilead Sciences

7.9.1 Gilead Sciences Profile

7.9.2 Gilead Sciences Main Business

7.9.3 Gilead Sciences Oligonucleotide Therapy Products, Services and Solutions

7.9.4 Gilead Sciences Oligonucleotide Therapy Revenue (US$ Million) & (2019-2024)

7.9.5 Gilead Sciences Recent Developments

8 Industry Chain Analysis

8.1 Oligonucleotide Therapy Industrial Chain

8.2 Oligonucleotide Therapy Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Oligonucleotide Therapy Sales Model

8.5.2 Sales Channel

8.5.3 Oligonucleotide Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Alnylam Pharmaceuticals Inc

Dynavax Technologies Corp

Merck and Co.

Miragen Therapeuutics Inc.

Sarepta Therapeutics Inc

List of Tables

Table 1. Oligonucleotide Therapy Market Trends

Table 2. Oligonucleotide Therapy Market Drivers & Opportunity

Table 3. Oligonucleotide Therapy Market Challenges

Table 4. Oligonucleotide Therapy Market Restraints

Table 5. Global Oligonucleotide Therapy Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Oligonucleotide Therapy Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Oligonucleotide Therapy Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Oligonucleotide Therapy Product Type

Table 9. Key Companies Time to Begin Mass Production of Oligonucleotide Therapy

Table 10. Global Oligonucleotide Therapy Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapy as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Oligonucleotide Therapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Oligonucleotide Therapy Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Oligonucleotide Therapy Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Oligonucleotide Therapy Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Oligonucleotide Therapy Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Oligonucleotide Therapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Oligonucleotide Therapy Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Oligonucleotide Therapy Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Oligonucleotide Therapy Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Oligonucleotide Therapy Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Oligonucleotide Therapy Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Oligonucleotide Therapy Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Oligonucleotide Therapy Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Oligonucleotide Therapy Sales Value by Region (2019-2024) & (%)

Table 27. Global Oligonucleotide Therapy Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Oligonucleotide Therapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Oligonucleotide Therapy Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Oligonucleotide Therapy Sales Value, (2025-2030) & (US$ Million)

Table 31. Alnylam Pharmaceuticals Inc. Basic Information List

Table 32. Alnylam Pharmaceuticals Inc. Description and Business Overview

Table 33. Alnylam Pharmaceuticals Inc. Oligonucleotide Therapy Products, Services and Solutions

Table 34. Revenue (US$ Million) in Oligonucleotide Therapy Business of Alnylam Pharmaceuticals Inc. (2019-2024)

Table 35. Alnylam Pharmaceuticals Inc. Recent Developments

Table 36. Biogen Basic Information List

Table 37. Biogen Description and Business Overview

Table 38. Biogen Oligonucleotide Therapy Products, Services and Solutions

Table 39. Revenue (US$ Million) in Oligonucleotide Therapy Business of Biogen (2019-2024)

Table 40. Biogen Recent Developments

Table 41. Dynavax Technologies Corp. Basic Information List

Table 42. Dynavax Technologies Corp. Description and Business Overview

Table 43. Dynavax Technologies Corp. Oligonucleotide Therapy Products, Services and Solutions

Table 44. Revenue (US$ Million) in Oligonucleotide Therapy Business of Dynavax Technologies Corp. (2019-2024)

Table 45. Dynavax Technologies Corp. Recent Developments

Table 46. Merck and Co. Basic Information List

Table 47. Merck and Co. Description and Business Overview

Table 48. Merck and Co. Oligonucleotide Therapy Products, Services and Solutions

Table 49. Revenue (US$ Million) in Oligonucleotide Therapy Business of Merck and Co. (2019-2024)

Table 50. Merck and Co. Recent Developments

Table 51. Miragen Therapeuutics Inc. Basic Information List

Table 52. Miragen Therapeuutics Inc. Description and Business Overview

Table 53. Miragen Therapeuutics Inc. Oligonucleotide Therapy Products, Services and Solutions

Table 54. Revenue (US$ Million) in Oligonucleotide Therapy Business of Miragen Therapeuutics Inc. (2019-2024)

Table 55. Miragen Therapeuutics Inc. Recent Developments

Table 56. Sarepta Therapeutics Inc. Basic Information List

Table 57. Sarepta Therapeutics Inc. Description and Business Overview

Table 58. Sarepta Therapeutics Inc. Oligonucleotide Therapy Products, Services and Solutions

Table 59. Revenue (US$ Million) in Oligonucleotide Therapy Business of Sarepta Therapeutics Inc. (2019-2024)

Table 60. Sarepta Therapeutics Inc. Recent Developments

Table 61. GlaxoSmithKline Basic Information List

Table 62. GlaxoSmithKline Description and Business Overview

Table 63. GlaxoSmithKline Oligonucleotide Therapy Products, Services and Solutions

Table 64. Revenue (US$ Million) in Oligonucleotide Therapy Business of GlaxoSmithKline (2019-2024)

Table 65. GlaxoSmithKline Recent Developments

Table 66. Pfizer Basic Information List

Table 67. Pfizer Description and Business Overview

Table 68. Pfizer Oligonucleotide Therapy Products, Services and Solutions

Table 69. Revenue (US$ Million) in Oligonucleotide Therapy Business of Pfizer (2019-2024)

Table 70. Pfizer Recent Developments

Table 71. Gilead Sciences Basic Information List

Table 72. Gilead Sciences Description and Business Overview

Table 73. Gilead Sciences Oligonucleotide Therapy Products, Services and Solutions

Table 74. Revenue (US$ Million) in Oligonucleotide Therapy Business of Gilead Sciences (2019-2024)

Table 75. Gilead Sciences Recent Developments

Table 76. Key Raw Materials Lists

Table 77. Raw Materials Key Suppliers Lists

Table 78. Oligonucleotide Therapy Downstream Customers

Table 79. Oligonucleotide Therapy Distributors List

Table 80. Research Programs/Design for This Report

Table 81. Key Data Information from Secondary Sources

Table 82. Key Data Information from Primary Sources

Table 83. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Oligonucleotide Therapy Product Picture

Figure 2. Global Oligonucleotide Therapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Oligonucleotide Therapy Sales Value (2019-2030) & (US$ Million)

Figure 4. Oligonucleotide Therapy Report Years Considered

Figure 5. Global Oligonucleotide Therapy Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Oligonucleotide Therapy Revenue in 2023

Figure 7. Oligonucleotide Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Antisense Oligonucleotide Picture

Figure 9. Aptamer Picture

Figure 10. Others Picture

Figure 11. Global Oligonucleotide Therapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Oligonucleotide Therapy Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Infectious Diseases

Figure 14. Product Picture of Oncology

Figure 15. Product Picture of Neurodegenerative Disorders

Figure 16. Product Picture of Cardiovascular Diseases

Figure 17. Product Picture of Kidney Diseases

Figure 18. Product Picture of Others

Figure 19. Global Oligonucleotide Therapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 20. Global Oligonucleotide Therapy Sales Value Market Share by Application, 2023 & 2030

Figure 21. North America Oligonucleotide Therapy Sales Value (2019-2030) & (US$ Million)

Figure 22. North America Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

Figure 23. Europe Oligonucleotide Therapy Sales Value (2019-2030) & (US$ Million)

Figure 24. Europe Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

Figure 25. Asia Pacific Oligonucleotide Therapy Sales Value (2019-2030) & (US$ Million)

Figure 26. Asia Pacific Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

Figure 27. South America Oligonucleotide Therapy Sales Value (2019-2030) & (US$ Million)

Figure 28. South America Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

Figure 29. Middle East & Africa Oligonucleotide Therapy Sales Value (2019-2030) & (US$ Million)

Figure 30. Middle East & Africa Oligonucleotide Therapy Sales Value by Country (%), 2023 VS 2030

Figure 31. Key Countries/Regions Oligonucleotide Therapy Sales Value (%), (2019-2030)

Figure 32. United States Oligonucleotide Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 33. United States Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

Figure 34. United States Oligonucleotide Therapy Sales Value by Application (%), 2023 VS 2030

Figure 35. Europe Oligonucleotide Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 36. Europe Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

Figure 37. Europe Oligonucleotide Therapy Sales Value by Application (%), 2023 VS 2030

Figure 38. China Oligonucleotide Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 39. China Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

Figure 40. China Oligonucleotide Therapy Sales Value by Application (%), 2023 VS 2030

Figure 41. Japan Oligonucleotide Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 42. Japan Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

Figure 43. Japan Oligonucleotide Therapy Sales Value by Application (%), 2023 VS 2030

Figure 44. South Korea Oligonucleotide Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 45. South Korea Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

Figure 46. South Korea Oligonucleotide Therapy Sales Value by Application (%), 2023 VS 2030

Figure 47. Southeast Asia Oligonucleotide Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 48. Southeast Asia Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

Figure 49. Southeast Asia Oligonucleotide Therapy Sales Value by Application (%), 2023 VS 2030

Figure 50. India Oligonucleotide Therapy Sales Value, (2019-2030) & (US$ Million)

Figure 51. India Oligonucleotide Therapy Sales Value by Type (%), 2023 VS 2030

Figure 52. India Oligonucleotide Therapy Sales Value by Application (%), 2023 VS 2030

Figure 53. Oligonucleotide Therapy Industrial Chain

Figure 54. Oligonucleotide Therapy Manufacturing Cost Structure

Figure 55. Channels of Distribution (Direct Sales, and Distribution)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Substrate Cutting Device Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-23Z18292

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Targeted Radionuclide Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-14Z15017

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global Microfluidic Single-Cell Analysis and Screening System Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-7M18883

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Medicinal Liquid Filling Equipment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37J14968

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions